Australia’s active vaccine safety system

Data on this page show the responses of individuals aged 5–11 years who received a paediatric 5–11 years formulation of the Pfizer COVID-19 vaccine (both monovalent original and XBB.1.5 variant) and whose parent or carer completed an AusVaxSafety survey on their behalf sent on day 3 after vaccination. These data provide a profile of what to expect in the days following a child’s Pfizer COVID-19 vaccination and can assist when planning for a child’s COVID-19 vaccination. Data on this page are updated monthly.


AusVaxSafety’s active vaccine safety surveillance system complements the enhanced safety surveillance activities of the Therapeutic Goods Administration (TGA). Find out more about how the TGA monitors the safety of vaccines and how you can report side effects on the TGA website.